Long‐term follow‐up of 3‐month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial

Authors:

Abstract
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE: To report our long‐term follow‐up of an institutional randomized prospective trial of radical prostatectomy (RP) with or without a 3‐month course of neoadjuvant hormone therapy (NHT), which results in pathological downstaging, but generally no reduction in biochemical recurrence (BCR) on early follow‐up (at 3 years). PATIENTS AND METHODS: From December 1992 to June 1996, 148 patients with clinically localized prostate cancer were randomized to RP only or 3 months of goserelin acetate and flutamide before RP. BCR was defined as a detectable serum prostate specific antigen level (>0.1 ng/mL) at least 6 weeks after surgery, with a confirmatory increase. RESULTS: The median follow‐up for BCR‐free patients was 8 years. There was no significant difference in BCR‐free probabilities between groups ( P = 0.7). The BCR‐free probability at 7 years was 78% for patients undergoing RP only and 80% for patients undergoing NHT and RP (difference of 2%; 95% confidence interval, CI, 12–16%). A Cox regression showed no significant relationship between NHT and BCR (hazard ratio 1.16; 95% CI, 0.56–2.39, P = 0.7). Overall, two patients had local recurrence and six developed metastases, and were evenly distributed among the RP only and NHT groups. CONCLUSION: Although our study was not originally powered to detect differences in BCR, there was no overall benefit in BCR‐free probability, local recurrence or metastasis with 3 months of NHT at 8 years of follow‐up. Pending evidence of improvement in patient outcomes, NHT before RP appears to be unjustified outside of clinical trials.

This publication has 35 references indexed in Scilit: